Framingham, Massachusetts-based Alzheon was awarded a $47 million grant over five years from the U.S. National Institute on Aging (NIA), part of the National Institutes of Health, to assist with a Phase III clinical trial of ALZ-801.
A specially designed clinical study that was the first disease prevention trial to study Alzheimer’s disease drugs with different mechanisms of action from two different pharmaceutical companies failed to hit the primary endpoint.
Carlsbad, California-based Ionis Pharmaceuticals licensed the company’s IONIS-MAPTRX antisense therapy to leading biotech firm Biogen Inc.
Researchers at Temple University Health System have shown that a type of energy malfunction, called mitochondrial calcium transport remodeling, is involved in the progression of Alzheimer’s disease.
Researchers with Massachusetts General Hospital have identified some crosstalk communication between TREM2 and CD33, two genes that play a role in inflammation and Alzheimer’s disease.
Novartis, Amgen and the Banner Alzheimer’s Institute announced they are halting two pivotal Phase II/III clinical trials in the Alzheimer’s Prevention Initiative Generation Program.
As pharma companies struggle with developing a treatment for Alzheimer’s disease, researchers continue to find evidence that links the dreaded form of dementia to other medical and health issues. The latest news suggests a potential link between Alzheimer’s and menopause.
Researchers with the University of California, Los Angeles (UCLA) Health Sciences have identified two major groups of genes that, when mutated, results in overproduction of the tau protein, at least in mice.
U.S. regulators proposed lowering the bar for clinical trial success for experimental Alzheimer’s drugs.